Feb 10, 2011 by Brian Orelli, PhDBreathe Easier, Join the CompetitionNovartis' strategy is a good one.
Feb 9, 2011 by Brian Orelli, PhDThese FDA Approvals Aren't Guaranteed ForeverFollow the FDA's rules ... or else.
Feb 9, 2011 by Brian Orelli, PhDOnce a Decade Isn't Enough, ElanElan posts its first operating profit in 10 years.
Feb 8, 2011 by Brian Orelli, PhDWhat Will Intuitive Surgical Do for an Encore? Ask the CEO about recent results during a Fool.com chat.
Feb 8, 2011 by Brian Orelli, PhDA Few Extra Years of Sales? Yes, Please!An EU-Canadian proposal could help drugmakers.
Feb 7, 2011 by Brian Orelli, PhDZibotentan Stopped, Long Live Provenge (for Now)Dendreon is looking good although it's not out of the woods yet.
Feb 4, 2011 by Brian Orelli, PhDGlaxo Sold Quest Shares. Should You?Only if you have a better place to put the capital to work.
Feb 3, 2011 by Brian Orelli, PhDAdd This Stock to Your Show-Me ListWait for the turnaround before investing in Boston Scientific -- if it ever comes.
Feb 3, 2011 by Brian Orelli, PhDGet Ready for Merck's Bumpy RideLong-term earnings guidance gets thrown out the window.
Feb 2, 2011 by Brian Orelli, PhDPfizer's Newest Acquisition Target Pfizer to drug developers: We're cheaper than you are.
Feb 1, 2011 by Brian Orelli, PhDOrexigen Falls ShortIts obesity drug fails in the final mile of the drug-development marathon.
Jan 31, 2011 by Brian Orelli, PhD5 Drugmakers Headed Back to the Drawing BoardSometimes an FDA rejection is more of a to-do list.
Jan 31, 2011 by Brian Orelli, PhDDrug Approved! Now Who's Going to Launch It?Depomed gets pain-free news from the FDA.
Jan 31, 2011 by Brian Orelli, PhDTime to Buy Into Stem Cells?New developments bring this Fool a step closer to opening his wallet.
Jan 31, 2011 by Brian Orelli, PhDBetter Buy: Amarin or Clinical Data?A battle of the takeover targets.
